GlassScriptPhysician profile
Brandon Johnson
NPI 1336766344
$5,053.82
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,850 · 2022: $2,002 · 2023: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.07 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $421.63 | 2021-2022 | |
| Sk Life Science, INC. | $363.22 | 2021-2022 | |
| Boston Scientific Corporation | $348.48 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $339.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $252.14 | 2021-2022 | |
| Neurelis, INC. | $215.26 | 2021-2023 | Valtoco |
| Novo Nordisk INC | $209.16 | 2021-2022 | |
| Daiichi Sankyo INC. | $176.28 | 2021-2022 | |
| Lundbeck LLC | $173.09 | 2021-2022 | |
| Glaxosmithkline, LLC. | $165.34 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $161.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $160.25 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.26 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.76 | 2021-2023 | Trintellix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.